Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Salix

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    8 result(s) found for: Salix. Displaying page 1 of 1.
    EudraCT Number: 2020-005232-30 Sponsor Protocol Number: AMUC-2023 Start Date*: 2021-06-21
    Sponsor Name:Salix Pharmaceuticals, Inc.
    Full Title: A Phase 2, Randomized, Double-Blinded, Placebo-Controlled, Parallel Group Study Evaluating the Efficacy and Safety of Amiselimod (MT-1303) in Subjects with Mild to Moderate Ulcerative Colitis (UC)
    Medical condition: Ulcerative Colitis (UC)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004856 10045365 Ulcerative colitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) EE (Completed) DE (Completed) CZ (Completed) BG (Completed) SK (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-001645-24 Sponsor Protocol Number: RECD3126 Start Date*: 2014-11-18
    Sponsor Name:Salix Pharmaceuticals, Inc.
    Full Title: A Double-Blind, Placebo-Controlled, Parallel-Group, Multicentre, Multiregional, One Year Study to Assess the Efficacy and Safety of Twice Daily Oral Rifaximin Delayed Release Tablets for Induction ...
    Medical condition: Treatment of active Crohn’s disease
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004856 10013099 Disease Crohns LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) CZ (Prematurely Ended) DE (Prematurely Ended) PL (Prematurely Ended) FR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-001644-38 Sponsor Protocol Number: RECD3125 Start Date*: 2014-11-18
    Sponsor Name:Salix Pharmaceuticals, Inc.
    Full Title: A Double-Blind, Placebo-Controlled, Parallel-Group, Multicentre, Multiregional, One Year Study to Assess the Efficacy and Safety of Twice Daily Oral Rifaximin Delayed Release Tablets for Induction ...
    Medical condition: Treatment of active Crohn’s disease
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004856 10013099 Disease Crohns LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) DE (Prematurely Ended) CZ (Prematurely Ended) PL (Prematurely Ended) FR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-002394-22 Sponsor Protocol Number: RFIB3053 Start Date*: 2013-09-26
    Sponsor Name:Salix Pharmaceuticals, Inc.
    Full Title: A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects with Irritable Bowel Syndrome with Diarrhoea (IBS-D)
    Medical condition: Irritable bowel syndrome (IBS) is a heterogeneous gastrointestinal (GI) disorder characterized by frequent and debilitating symptoms (e.g. diarrhoea, bloating, abdominal pain, urgency to defecate, ...
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004856 10060849 Diarrhoea predominant irritable bowel syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-000883-27 Sponsor Protocol Number: Rif_CVID_260611 Start Date*: 2013-08-16
    Sponsor Name:Oslo University hospital
    Full Title: EFFECTS OF RIFAXIMIN, BY MODULATION OF THE GUT MICROBIOTA, ON MARKERS OF SYSTEMIC INFLAMMATION IN PATIENTS WITH COMMON VARIABLE IMMUNODEFICIENCY - AN EXPLORATORY OPEN-LABEL RANDOMIZED CONTROLLED TRIAL
    Medical condition: Adult patients with the diagnosis of Common variable deficiency and fulfill the inclusion and exclusion criteria, will be invited to participate in the study.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-000192-27 Sponsor Protocol Number: GutHeart1 Start Date*: 2015-03-19
    Sponsor Name:Oslo University Hospital
    Full Title: GutHeart: Targeting Gut microbiota to treat Heart failure
    Medical condition: Heart failure
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-006107-20 Sponsor Protocol Number: 3200K1-4001-WW(B2541006) Start Date*: 2009-02-27
    Sponsor Name:Salix Pharmaceuticals Inc.
    Full Title: Open-Label Extension Study to Assess the Safety of a Fixed Dose of Subcutaneous Methylnaltrexone in Subjects With Advanced Illness and Opioid-Induced Constipation
    Medical condition: Opioid-induced constipation
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) FR (Completed) FI (Prematurely Ended) DK (Prematurely Ended) PT (Completed) SE (Prematurely Ended) DE (Prematurely Ended) BE (Prematurely Ended) IT (Prematurely Ended) ES (Completed)
    Trial results: View results
    EudraCT Number: 2007-000854-30 Sponsor Protocol Number: 3200K1-4000-WW(B2541005) Start Date*: 2009-02-27
    Sponsor Name:Salix Pharmaceuticals Inc.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Study of a Fixed Dose of Subcutaneous Methylnaltrexone in Adults With Advanced Illness and Opioid-Induced Constipation: Efficacy, Safety, and Addition...
    Medical condition: Opioid-induced constipation in subjects with advanced illness
    Disease: Version SOC Term Classification Code Term Level
    14.1 10017947 - Gastrointestinal disorders 10010774 Constipation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) ES (Prematurely Ended) FR (Completed) FI (Prematurely Ended) DK (Prematurely Ended) PT (Completed) SE (Prematurely Ended) DE (Prematurely Ended) BE (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 02 04:40:19 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA